Document 0324
 DOCN  M9590324
 TI    Pilot study of the efficacy of ateviridine in AIDS dementia complex
       (ADC).
 DT    9509
 AU    Brew B; Dunbar J; Druett J; Freund J; Ward P; National Centre in HIV
       Epidemiology and Clinical Research,; Darlinghurst Sydney, Australia.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:176 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291775
 AB    OBJECTIVE: To assess in a pilot study the efficacy of ateviridine
       (U-87201E, Upjohn Laboratories), a member of the BHAP class of
       antiretroviral drugs, in the treatment of ADC. METHODS: Ten ADC patients
       (combined neurological and neuropsychological impairment score > 4
       (normal < or = 4), were enrolled in an open study of ateviridine 600mg
       tds for 12 weeks with the option for continuation of supply. Regular
       neurological, neuropsychological assessments were performed along with
       CSF analyses, MRI and HMPAO SPECT. RESULTS: Five of the 10 patients
       completed the protocol. Four of these 5 responded to ateviridine: mean
       combined impairment score 19.6 at week 0 and 5 at week 12. Two patients
       improved from stage 2 to 0 and 2 from 1 to 0.5. CSF beta 2 microglobulin
       and neopterin concentrations also improved (mean 5.48 and 39.45
       respectively at week 0; 4.55 and 25.07 at week 12). Of the patients who
       did not complete the protocol 2 died of sepsis, 1 developed PML, 1 died
       of hypotension and 1 developed a rash. Of the patients who completed the
       protocol, one suicided at week 12; one remained free of ADC until week
       33 when he ceased the drug because of of lymphoma and died 3 weeks later
       of progressive ADC, one patient ceased the drug in the context of
       septicaemia and died and one patient has been lost to follow up.
       CONCLUSIONS: Ateviridine is effective in the treatment of ADC. This
       pilot study highlights the utility of ADC as a clinical endpoint in the
       assessment of the efficacy of new antiretroviral agents.
 DE    Antiviral Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  AIDS Dementia
       Complex/*DRUG THERAPY  Human  Neurologic Examination/DRUG EFFECTS
       Neuropsychological Tests  Pilot Projects  Piperazines/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  Treatment Outcome  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).